1 |
Peddi PF, Lubner S, McWilliams R, et al (2012). Multiinstitutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP, 13, 497-501.
|
2 |
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
DOI
ScienceOn
|
3 |
Valsecchi ME, Diaz-Canton E, de la Vega M, Littman SJ (2014). Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. J Gastrointest Cancer.
|
4 |
Von Hoff DD, Ervin T, Arena FP et al (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 369, 1691-703.
DOI
|
5 |
Waraya M, Yamashita K, Katagiri H, et al (2009). Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol, 16, 1231-40.
DOI
|
6 |
Ballehaninna UK, Chamberlain RS (2012). The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol, 3, 105-19.
|
7 |
Bayoglui IV, Varoli U, Yildizi I, et al (2014). Second-line capecitabine and oxaliplatin combination for gemcitabineresistant advanced pancreatic cancer. Asian Pac J Cancer Prev, 15, 7119-23.
DOI
|
8 |
Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP (2004). Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol, 11, 644-9.
DOI
|
9 |
Burris HA 3rd, Moore M J, Andersen J, et al (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15, 2403-13.
|
10 |
Conroy T, Desseigne F, Ychou M, et al (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 364, 1817-25.
DOI
ScienceOn
|
11 |
Conroy T, Mitry E (2011). Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results. Bull Cancer, 98, 1439-46.
|
12 |
Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M (2013). The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep, 15, 182-9.
DOI
|
13 |
Cunningham D, Chau I, Stocken DD, et al (2009). Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol, 27, 5513-8.
DOI
|
14 |
Di Marco M, Di Cicilia R, Macchini M, et al (2010). Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncology reports, 23, 1183-92.
|
15 |
Gunturu KS, Yao X, Cong X, et al (2013). FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol, 30, 361.
DOI
|
16 |
Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J Clin, 55, 10-30.
DOI
|
17 |
Ko, A. H. (2011) FOLFIRINOX: a small step or a great leap forward? J Clin Oncol, 29, 3727-9.
DOI
|
18 |
Mahaseth H, Brutcher E, Kauh J, et al (2013). Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas, 42, 1311-5.
DOI
|
19 |
Parvez T, Dawood T (2003). Pancreatic cancer: new strategies available, but long battle ahead. J Coll Physicians Surg Pak, 13, 303-4.
|